Safety and Immunogenicity of Vi-DT Typhoid Conjugate Vaccine (Bio Farma) in Adults and Children (Phase I)

Inclusion Criteria: 1. Healthy 2. Subjects/Parents have been informed properly regarding the study and signed the informed consent form 3. Subject/Parents will commit to comply with the instructions of the investigator and the schedule of the trial Exclusion Criteria: 1. Subject concomitantly enrolled or scheduled to be enrolled in another trial 2. Evolving mild, moderate or severe illness, especially infectious diseases or fever (axillary temperature ³ 37.5°C ) 3. Known history of allergy to any component of the vaccines 4. History of uncontrolled coagulopathy or blood disorders contraindicating intramuscular injection 5. Subject who has received in the previous 4 weeks a treatment likely to alter the immune response (intravenous immunoglobulins, blood-derived products or long term corticotherapy (\> 2 weeks). 6. Any abnormality or chronic disease which according to the investigator might interfere with the assessment of the trial objectives 7. Pregnancy \& lactation (Adults) 8. Individuals who have previously received any vaccines against typhoid fever. 9. Subjects already immunized with any vaccine within 4 weeks prior and expect to receive other vaccines within 60 days following the first dose. 10. Individuals who have a previously ascertained typhoid fever. 11. History of alcohol or substance abuse. 12. Subject planning to move from the study area before the end of study period.